Hovione's 8Shot DPI qualifies as MDEA hotshot

Hovione Technology, a pharmaceutical specialist in innovative pulmonary device technology, has announced that its new 8Shot dry powder inhaler (DPI) has been chosen as finalist in the Drug-Delivery and Combination Products category of the 2021 Medical Design Excellence Awards (MDEA) competition.

“The MDEA competition is a premier awards program for the medtech industry. The selection of our 8Shot DPI to be among the list of finalists in the Drug-Delivery and Combination products category is a great achievement for the Hovione Technology team,” said Peter Villax, Hovione Technology’s CEO.

The 8Shot DPI is a high drug load inhaler specially designed to deliver inhaled vaccines, anti-virals, antibiotics and biologics requiring very high dose drug delivery and provides the largest delivery capability in the industry without compromising simplicity. It achieves ease of use by patients, by breaking down the delivery to the lung of the total drug dose in multiple inhalation steps for maximum therapeutic benefit and patient comfort. 

“We are honored and delighted to be a finalist of the MDEA competition, together with our design and development partner WeADD”, said Dr João Ventura Fernandes, Hovione Technology’s director of technology development and licensing. “This nomination recognises our medical product design efforts with the 8Shot DPI to make it as attractive and as easy to use as possible to patients, a necessary step to regular use and treatment compliance.”